文献速递前列腺癌

与异时性寡转移性去势敏感性前列腺癌进展模式和失败模式相关的基因组决定因素

Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2024-06-10

一项国际多中心回顾性研究纳入267例接受肿瘤二代测序的异时性寡转移性去势敏感性前列腺癌男性患者,分析基因组改变与首次治疗后进展模式及失败模式的相关性。TP53和RB1突变与更高的进展可能相关,TP53、SPOP和WNT通路突变可能在转移器官趋向性中起作用。

要点

  • TP53突变与较低的长期控制率相关(27.6% vs 42.3%,p=0.04)。
  • RB1突变与较高的多灶进展率相关(50% vs 19.9%,p=0.022)。
  • TP53突变者骨失败更常见(44.8% vs 25.9%,p=0.005)。

核心结论

  • 肿瘤基因组学为异时性寡转移性去势敏感性前列腺癌治疗后的进展模式和失败模式提供了新见解。
  • TP53和RB1突变患者进展可能性更高,TP53、SPOP和WNT通路突变可能在转移器官趋向性中起作用。

研究设计与样本

  • 国际多中心回顾性研究,纳入267例接受肿瘤二代测序且首次治疗后随访至少1年的异时性寡转移性去势敏感性前列腺癌男性患者。
  • 进展模式分为I类长期控制(末次随访无影像学进展)、II类寡进展(1-3个病灶)和III类多进展(≥4个病灶);失败模式包括首次失败时病灶位置。

主要发现

  • 267例患者中,47%有1个转移灶,30%有2个转移灶。
  • 3年总生存率与进展模式显著相关:多进展组71% vs 寡进展组91%(p=0.005)。
  • TP53突变与较低的长期控制率相关(27.6% vs 42.3%,p=0.04);RB1突变与较高的多进展率相关(50% vs 19.9%,p=0.022)。
  • 骨失败在TP53突变肿瘤中更常见(44.8% vs 25.9%,p=0.005),在SPOP突变肿瘤中较少见(7.1% vs 31.4%,p=0.007)。
  • 内脏失败在WNT通路突变肿瘤中更常见(17.2% vs 6.8%,p=0.05),在SPOP突变肿瘤中也更常见(17.9% vs 6.3%,p=0.04);内脏和骨失败与不同的基因表达谱相关。

关键数值与推荐

  • 原文未报告指南或共识推荐条款。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Oligometastatic castration-sensitive prostate cancer (omCSPC) represents an early state in the progression of metastatic disease for which patients experience better outcomes in comparison to those with higher disease burden. Despite the generally more indolent nature, there is still much heterogeneity, with some patients experiencing a more aggressive clinical course unexplained by clinical features alone. Our aim was to investigate correlation of tumor genomics with the mode of progression (MOP) and pattern of failure (POF) following first treatment (metastasis-directed and/or systemic therapy) for omCSPC. METHODS: We performed an international multi-institutional retrospective study of men treated for metachronous omCSPC who underwent tumor next-generation sequencing with at least 1 yr of follow-up after their first treatment. Descriptive MOP and POF results are reported with respect to the presence of genomic alterations in pathways of interest. MOP was defined as class I, long-term control (LTC; no radiographic progression at last follow-up), class II, oligoprogression (1-3 lesions), or class III, polyprogression (≥4 lesions). POF included the location of lesions at first failure. Genomic pathways of interest included TP53, ATM, RB1, BRCA1/2, SPOP, and WNT (APC, CTNNB1, RNF43). Genomic associations with MOP/POF were compared using χ2 tests. Exploratory analyses revealed that the COSMIC mutational signature and differential gene expression were also correlated with MOP/POF. Overall survival (OS) was calculated via the Kaplan-Meier method from the time of first failure. KEY FINDINGS AND CLINICAL IMPLICATIONS: We included 267 patients in our analysis; the majority had either one (47%) or two (30%) metastatic lesions at oligometastasis. The 3-yr OS rate was significantly associated with MOP (71% for polyprogression vs 91% for oligoprogression; p = 0.005). TP53 mutation was associated with a significantly lower LTC rate (27.6% vs 42.3%; p = 0.04) and RB1 mutation was associated with a high rate of polyprogression (50% vs 19.9%; p = 0.022). Regarding POF, bone failure was significantly more common with tumors harboring TP53 mutations (44.8% vs25.9%; p = 0.005) and less common with SPOP mutations (7.1% vs 31.4%; p = 0.007). Visceral failure was more common with tumors harboring either WNT pathway mutations (17.2% vs 6.8%, p = 0.05) or SPOP mutations (17.9% vs 6.3%; p = 0.04). Finally, visceral and bone failures were associated with distinct gene-expression profiles. CONCLUSIONS AND CLINICAL IMPLICATIONS: Tumor genomics provides novel insight into MOP and POF following treatment for metachronous omCSPC. Patients with TP53 and RB1 mutations have a higher likelihood of progression, and TP53, SPOP, and WNT pathway mutations may have a role in metastatic organotropism. PATIENT SUMMARY: We evaluated cancer progression after a first treatment for metastatic prostate cancer with up to five metastases. We found that mutations in certain genes were associated with the location and extent of further metastasis in these patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Sutera P, Song Y, Shetty AC, et al. Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer. Eur Urol Oncol. 2024. PMID: 38862340. doi:10.1016/j.euo.2024.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。